TrialMultiple sclerosis (Houndmills, Basingstoke, England)2018

Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis.

Ludwig Kappos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.